Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon. 1993

A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
Hospital Universitario Reina Sofia, University of Cordoba, Spain.

According to recent reports, fibrinolytic activity may be enhanced during hemodialysis. The aim of this work was to study the fibrinolytic activity in uremic patients, and to evaluate the effect of membrane biocompatibility on the fibrinolytic system during hemodialysis. Tissue plasminogen activator (t-PA), t-PA antigen, plasminogen activator-inhibitor (PAI), plasminogen (PL) and alpha-2-antiplasmin (AP) were measured in 10 uremic patients on maintenance hemodialysis treated sequentially with Cuprophane and polyacrylonitrile (AN69) membranes. Blood samples were obtained before and at 15, 60 and 120 minutes after the initiation of dialysis. Blood was also collected from 20 healthy individuals who served as controls. During cuprophane dialysis, t-PA increased significantly at 60 minutes (14.8 vs. 8.4 IU/ml, P < 0.05) and at 120 minutes (13.8 P < 0.01). This was accompanied by an increase in t-PA antigen, which was significant at 15 (5.1 vs. 13.1 ng/ml), 60 (15.2) and 120 (9.6) minutes (P < 0.05) of dialysis. However, during AN69 dialysis t-PA and t-PA antigen plasma levels remained stable. No significant changes were observed in PL, AP or PAI during hemodialysis with either membrane. In conclusion, hemodialysis enhances fibrinolytic activity, which is likely the result of t-PA Ag release. Therefore, this phenomenon seems to be closely related to dialysis membrane biocompatibility.

UI MeSH Term Description Entries
D008297 Male Males
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
August 1970, Japanese circulation journal,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
August 1992, Clinical nephrology,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
March 1988, Kidney international. Supplement,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
July 1985, Clinical nephrology,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
February 1998, The International journal of artificial organs,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
January 1980, Minerva nefrologica,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
November 1980, The Tohoku journal of experimental medicine,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
January 1972, Acta obstetricia et gynecologica Scandinavica,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
January 2020, Advances in experimental medicine and biology,
A Martin-Malo, and F Velasco, and R Rojas, and D Castillo, and M Rodriguez, and A Torres, and P Aljama
January 1988, Pediatrie,
Copied contents to your clipboard!